Literature DB >> 7872138

Psychiatric and behavioral abnormalities in Wilson's disease.

M Akil1, G J Brewer.   

Abstract

From the literature and our experience, a relatively consistent picture of psychiatric and behavioral abnormalities in Wilson's disease emerges. The essential elements of this picture are as follows: 1. Psychiatric and behavioral abnormalities are frequent manifestations of WD. The estimates range from 30% (18) to 100% (2) of symptomatic patients. As Wilson himself was the first to state in reference to "mental change," "its importance should not be underestimated." 2. Psychiatric and behavioral abnormalities are often the initial manifestations of WD. Two thirds of our patients first presented with psychiatric symptoms and one third received psychiatric treatment before the diagnosis of WD was made. In the early stages of the disease, when psychiatric and behavioral symptoms predominate, the diagnosis is often missed. Of our 124 patients, WD was diagnosed in only one during this phase. Until the psychiatric presentation of WD is recognized, and the disease is included in the differential diagnosis of psychiatric symptoms, its diagnosis will be missed or delayed. In our patients, and others' (13,15), the delay in diagnosis ranged from 1 to 5 years. Such a delay is particularly tragic as favorable outcome depends upon early discovery. 3. The most common of the psychiatric and behavioral manifestations of WD include: personality changes such as irritability and low threshold to anger, depression sometimes leading to suicidal ideation and attempts, deteriorating academic and work performance that is present in almost all neurologically affected patients. We (1) have also observed, as did Scheinberg and Sternlieb (2) that WD patients exhibit increased sexual preoccupation and reduced sexual inhibition. Finally, cognitive impairment, psychosis, anxiety, and other psychiatric disorders, although less frequent, also occur. 4. Some of the psychiatric and behavioral symptoms are reversible with WD-specific therapy, whereas others are not. We are impressed with the frequency with which the behavioral and "cognitive" symptoms are reversed over 1 to 2 years of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7872138

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  33 in total

Review 1.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 2.  Encephalopathy in Wilson disease: copper toxicity or liver failure?

Authors:  Peter Ferenci; Tomasz Litwin; Joanna Seniow; Anna Czlonkowska
Journal:  J Clin Exp Hepatol       Date:  2014-09-22

3.  Hepatobiliary Quiz (Answers)-14 (2015).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2015-06-27

Review 4.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

5.  Complex psychiatric presentation in adolescent onset Wilson's disease.

Authors:  S Woerwag-Mehta; Peter Hindley; Tammy Hedderly; Anil Dhawan
Journal:  BMJ Case Rep       Date:  2011-01-11

6.  Misdiagnosis of Wilson's Disease in a Patient with Psychiatric Symptoms.

Authors:  Doval Nimisha; Batra Dhruv; Moun Vikas; Jha K Sneh; Shukla Rakesh
Journal:  Indian J Psychol Med       Date:  2016 Jul-Aug

7.  Psychiatric manifestations of Wilson's disease and treatment with electroconvulsive therapy.

Authors:  Manoj Kumar Sahoo; Ajit Avasthi; Madhusmita Sahoo; Manish Modi; Parthasarathy Biswas
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

Review 8.  Sleep Abnormalities in Wilson's Disease.

Authors:  Valérie Cochen De Cock; Nadège Girardot-Tinant; France Woimant; Aurélia Poujois
Journal:  Curr Treat Options Neurol       Date:  2018-09-27       Impact factor: 3.598

Review 9.  Copper signaling in the mammalian nervous system: synaptic effects.

Authors:  E D Gaier; B A Eipper; R E Mains
Journal:  J Neurosci Res       Date:  2012-11-01       Impact factor: 4.164

10.  Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease.

Authors:  Mario Piga; Alessandra Murru; Loredana Satta; Alessandra Serra; Alessandro Sias; Gianluigi Loi; Francesco Marrosu; Luigi Demelia
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-08       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.